Epizyme, Inc. EPZM
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Market cap
- 247.50M
- Revenue (ttm)
- 53.01M
- Shares out
- 168.36M
- Forward P/E
- -0.67
- Open
- 1.49
- Previous close
- 1.47
- Day's range
- 1.47 – 1.50
- Beta
- -0.42
- Analysts
- Buy
- Price target
- 6.00 (+308.2%)
- Earnings date
- Aug 9, 2022
Key statistics
- Enterprise value
- 356.82M
- PEG ratio
- -0.02
- Price / sales
- 4.67
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 111.60%
- Free cash flow
- -127.80M
- Total cash
- 144.41M
- Total debt
- 253.73M
- Return on equity
- -877.48%
- Short % of float
- 2.32%
- 50-day average
- 1.25
- 200-day average
- 1.67
Analyst view
Consensus: buy
- Strong buy5
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 9, 2022
Expected Aug 9, 2022. Consensus EPS estimate -0.41.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2022 | Jun 1, 2022 | -0.36 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.35 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -0.41 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.45 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -0.60 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.56 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 28, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| Jun 27, 2022 | Wedbush | down | Outperform | Neutral |
| Jun 3, 2022 | HC Wainwright & Co. | main | — | Buy |
| May 12, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 2, 2022 | HC Wainwright & Co. | main | — | Buy |
| Aug 10, 2021 | Morgan Stanley | down | Equal-Weight | Underweight |
About Epizyme, Inc.
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- epizyme.com
News
Ipsen to acquire Epizyme, expanding its portfolio in oncology 
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology 
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology 
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y 
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates 
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update 
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM 
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
Your note
Sign in to keep a note on EPZM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGARWAL SHEFALI | Officer | Conversion of Exercise of derivative security | Aug 8, 2022 | 285,562 |
| BATE KENNETH M | Director | Stock Award(Grant) | May 16, 2022 | 17,054 |
| BEAULIEU JOSEPH | Officer | Conversion of Exercise of derivative security | Aug 8, 2022 | 51,099 |
| BEVERIDGE ROY A M.D. | Director | Stock Award(Grant) | Jun 29, 2022 | 46,037 |
| BOGLE GRANT C | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 8, 2022 | 259,170 |
| CONROY KEVIN T | Director | Stock Award(Grant) | Jun 29, 2022 | 62,318 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RP Management, LLC | 18.91% | 31,841,394 | 46.81M | Jun 29, 2022 |
| Primecap Management Company | 9.88% | 16,642,727 | 24.46M | Jun 29, 2022 |
| Blackrock Inc. | 6.40% | 10,778,038 | 15.84M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 4.48% | 7,540,469 | 11.08M | Jun 29, 2022 |
| Rock Springs Capital Management, LP | 4.32% | 7,267,696 | 10.68M | Mar 30, 2022 |
| Palo Alto Investors Lp | 4.02% | 6,774,541 | 9.96M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Odyssey Aggressive Growth Fund | 6.38% | 10,744,756 | 15.79M | Jun 29, 2022 |
| Primecap Odyssey Growth Fund | 2.86% | 4,821,843 | 7.09M | Jun 29, 2022 |
| Vanguard Total Stock Market Index Fund | 2.15% | 3,626,874 | 5.33M | Mar 30, 2022 |
| iShares Russell 2000 ETF | 1.79% | 3,016,455 | 4.43M | May 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 1.56% | 2,621,335 | 3.85M | May 30, 2022 |
| Vanguard Extended Market Index Fund | 1.50% | 2,519,574 | 3.70M | Mar 30, 2022 |